Headache and Migraine

Nuri Jacoby, MD, neurologist at Maimonides Medical Center and SUNY Downstate, previewed a hands-on session at the upcoming AUP Annual Meeting exploring how simulations can teach communication, professionalism, and feedback skills in neurology training.

The professor and chair of neuroscience at UT Southwestern Medical Center offered an overview on his keynote lecture presented at AHS 2025 on the circadian clock in relation to headache.

Patients using intranasal zavegepant for acute migraines report significant pain relief and improved daily functioning, highlighting its real-world effectiveness.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 11, 2025.

A recent survey reveals rimegepant's effectiveness for short-term migraine prevention, highlighting user demographics, triggers, and treatment strategies.

Eptinezumab showed significant efficacy in reducing chronic migraine days in Asian patients, potentially addressing a critical unmet need for effective treatments.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 4, 2025.

Catch up on any of the neurology news headlines you may have missed over the course of June 2025, compiled all into one place by the NeurologyLive® team.

The director of the MedStar Georgetown Headache Center discussed results from the phase 3 TEMPLE trial, which showed improved tolerability and cognitive outcomes with atogepant vs topiramate in episodic migraine. [WATCH TIME: 5 minutes]

Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could potentially reshape patient care.

Neurology News Network. for the week ending June 28, 2025. [WATCH TIME: 4 minutes]

A recent survey reveals critical gaps in neurology training on women's health, highlighting the need for urgent curriculum reforms in medical education.

New findings reveal eptinezumab significantly reduces migraine days and medication use in chronic migraine patients, offering hope for effective treatment.

Chia-Chun Chiang, MD, associate professor of neurology at Mayo Clinic Rochester, discussed how AI-based ECG and imaging tools can aid in predicting stroke and cardiovascular outcomes in patients with migraine.

The chair of neurology at the University of South Carolina discussed findings from a study recently presented at AHS 2025 that linked migraine to autonomic dysfunction, increased risk of atrial fibrillation, and cardioembolic stroke. [WATCH TIME: 5 minutes]

The professor of neurology at the Geisel School of Medicine at Dartmouth broke down the clinical utility, supporting data, and practical use cases for STS101, a newly approved nasal powder formulation of dihydroergotamine for acute migraine.

Fremanezumab shows significant long-term effectiveness in reducing migraine frequency and severity, enhancing patient outcomes in chronic and episodic cases.

The neurologist and headache specialist at the Montreal Neurological Clinic spoke about a recent national survey presented at AHS 2025 that revealed insightful patient perspectives in migraine. [WATCH TIME: 5 minutes]

The professor of neurology at the Geisel School of Medicine at Dartmouth broke down the FDA approval of STS101, a new DHE nasal powder, and its implications for acute migraine care. [WATCH TIME: 7 minutes]

Jennifer Robblee, MD, MSc, headache neurologist at the Barrow Neurological Institute, talked about an expert panel that developed a consensus definition for refractory migraine.

Nathaniel M. Schuster, MD, associate clinic director at the UC San Diego, talked about findings from a study of vaporized cannabis in treating patients with acute migraine presented at AHS 2025.

Laura Sebrow, PhD, a post doctoral neuropsychology fellow at North Shore University Hospital, discussed the relationship between patients’ reported cognitive difficulties and measurable cognitive performance during different migraine phases.

Marcela Romero-Reyes, DDS, PhD, FAHS, director of the Brotman Facial Pain Clinic at the University of Maryland, discussed a promising and potentially safer therapeutic approach for managing trigeminal neuropathic pain.

Neurology News Network. for the week ending June 21, 2025. [WATCH TIME: 4 minutes]

The director of outpatient care at Jefferson Headache Center weighed in on the future of PACAP as a migraine target and previewed upcoming innovations at the 2025 AHS Annual Meeting. [WATCH TIME: 3 minutes]

Atogepant outperforms topiramate in migraine prevention, showcasing superior efficacy and safety in the phase 3 TEMPLE trial results.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Migraine Awareness Month

The director of outpatient care at Jefferson Headache Center reflected on advances in migraine care and the ongoing outpatient challenges in treating this widespread yet under-recognized condition. [WATCH TIME: 3 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of May 2025, compiled all into one place by the NeurologyLive® team.

A recent study revealed that rizatriptan was ineffective for treating vestibular migraine attacks, showing limited symptom relief compared with placebo.